Cantor Fitzgerald Reaffirms “Overweight” Rating for Pfizer (NYSE:PFE)

Cantor Fitzgerald reissued their overweight rating on shares of Pfizer (NYSE:PFEFree Report) in a report published on Thursday, Benzinga reports. Cantor Fitzgerald currently has a $45.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on PFE. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a neutral rating in a research note on Wednesday, July 31st. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an equal weight rating in a report on Wednesday, July 31st. StockNews.com cut shares of Pfizer from a buy rating to a hold rating in a report on Tuesday, October 1st. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an equal weight rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a moderate buy rating to a strong-buy rating in a report on Wednesday, August 7th. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $34.54.

Read Our Latest Stock Analysis on PFE

Pfizer Stock Up 0.8 %

Pfizer stock opened at $28.58 on Thursday. The firm has a market cap of $161.95 billion, a price-to-earnings ratio of -476.33, a PEG ratio of 1.25 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer has a 12 month low of $25.20 and a 12 month high of $33.92. The stock has a fifty day simple moving average of $29.17 and a two-hundred day simple moving average of $28.32.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the firm posted $0.67 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities analysts predict that Pfizer will post 2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares during the period. Marshall Wace LLP lifted its position in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the period. Swedbank AB bought a new position in shares of Pfizer during the first quarter valued at approximately $172,902,000. Pzena Investment Management LLC increased its holdings in Pfizer by 181.6% during the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after buying an additional 4,947,000 shares during the period. Finally, FIL Ltd raised its stake in Pfizer by 97.1% in the fourth quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock worth $218,301,000 after buying an additional 3,734,595 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.